Galena (GALE) Presents New Data on SN-33, NeuVax Phase 1/2
Tweet Send to a Friend
Galena Biopharma (Nasdaq: GALE) presented data from the completed SN-33 Trial and final results from the Phase 1/2 trials of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
